-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest news, Novartis spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec) has been approved to be included in the British National Health Service (NHS).
Novartis' gene therapy for spinal muscular atrophy, Zolgensma, is considered the most expensive drug in the world.
Novartis Zolgensma is the first gene therapy to treat spinal muscular atrophy.
Spinal muscular atrophy is a difficult disease in which the loss of specific gene function leads to a decrease in muscle strength.
External analysis believes that Zolgensma has been successfully incorporated into the British medical insurance system, paving the way for the National Institute of Health and Clinical Optimization (NICE), the UK's price regulator, to finally approve the drug.